Global Blood Therapeutics (NASDAQ:GBT): Q3 GAAP EPS of -$1.07 misses by $0.01.
Cash, cash equivalents and marketable securities of $683.1M.
Shares +0.65% AH.
Thursday, November 7, 2019
Eiger BioPharmaceuticals EPS in-line
Eiger BioPharmaceuticals (NASDAQ:EIGR): Q3 GAAP EPS of -$0.76 in-line.
Cash, cash equivalents, and short-term investments of $109.9M.
Assembly Biosciences EPS misses by $0.03, beats on revenue
Assembly Biosciences (NASDAQ:ASMB): Q3 GAAP EPS of -$0.96 misses by $0.03.
Revenue of $4.23M (-1.4% Y/Y) beats by $0.79M.
BridgeBio Pharma EPS beats by $0.04
BridgeBio Pharma (NASDAQ:BBIO): Q3 GAAP EPS of -$0.51 beats by $0.04.
Cash, cash equivalents and marketable securities of $446.1M
Stemline Therapeutics EPS beats by $0.12, misses on revenue
Stemline Therapeutics (NASDAQ:STML): Q3 GAAP EPS of -$0.34 beats by $0.12.
Revenue of $13.33M misses by $0.31M.
Shares -4.21% AH.
IGM Biosciences reports Q3 results
IGM Biosciences (NASDAQ:IGMS): Q3 GAAP EPS of -$2.41.
Cash and investments of $251.35M.
Flexion Therapeutics EPS misses by $0.03, beats on revenue
Flexion Therapeutics (NASDAQ:FLXN): Q3 GAAP EPS of -$1.00 misses by $0.03.
Revenue of $21.79M (+211.7% Y/Y) beats by $2.78M.
Shares -0.9%.
Subscribe to:
Comments (Atom)